Publications
July 22, 2024
Frontiers in Neurology
Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study
July 9, 2024
Science Signaling
An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis
February 9, 2024
Neurology
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
Posters & Presentations
November 2024
Society for Immunotherapy of Cancer (SITC) 2024
DRAGON trial: durable remission rate with the latent TGFβ1 inhibitor linavonkibart (SRK-181) and pembrolizumab in patients with immune checkpoint inhibitor–resistant advanced cancers
November 2024
ObesityWeek 2024
SRK-439 Selectively Inhibits Myostatin to Promote Healthy Body Composition During Metformin Therapy
October 2024
World Muscle Society Annual Congress
Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: Results from the 48-month TOPAZ study